Literature DB >> 23797640

The hyper IgM syndromes.

Nashmia Qamar1, Ramsay L Fuleihan.   

Abstract

The hyper IgM syndromes are a group of rare inherited immune deficiency disorders characterized by impairment of immunoglobulin isotype switching resulting from defects in the CD40 ligand/CD40 signaling pathway. X-linked forms of hyper IgM are caused by defects in the CD40 ligand gene or NF-κB essential modulator, while autosomal recessive forms of hyper IgM are caused by defects in CD40 or downstream signaling molecules including activation-induced cytidine deaminase, uracil N glycosylase or postmeiotic segregation increased 2. The loss of interaction between CD40 and its ligand results in an impairment of T cell function, of B cell differentiation and of monocyte function while only B cell differentiation appears to be affected in defects of sinaling molecules downstream of CD40 with the exception of defects of the NF-κB complex, which mediates signaling via multiple receptor pathways. With many genetic defects in the hyper IgM syndrome identified, it is possible to diagnose patients definitively, to perform genetic screening, and to delineate the clinical manifestations of the different diseases in this syndrome. Stem cell transplantation is an available therapeutic option for defects that result in a combined immunodeficiency while antibody replacement appears sufficient for the strictly humoral immunodeficiencies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23797640     DOI: 10.1007/s12016-013-8378-7

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  108 in total

1.  Clinical spectrum of X-linked hyper-IgM syndrome.

Authors:  J Levy; T Espanol-Boren; C Thomas; A Fischer; P Tovo; P Bordigoni; I Resnick; A Fasth; M Baer; L Gomez; E A Sanders; M D Tabone; D Plantaz; A Etzioni; V Monafo; M Abinun; L Hammarstrom; T Abrahamsen; A Jones; A Finn; T Klemola; E DeVries; O Sanal; M C Peitsch; L D Notarangelo
Journal:  J Pediatr       Date:  1997-07       Impact factor: 4.406

2.  Defective expression of the CD40 ligand in X chromosome-linked immunoglobulin deficiency with normal or elevated IgM.

Authors:  R Fuleihan; N Ramesh; R Loh; H Jabara; R S Rosen; T Chatila; S M Fu; I Stamenkovic; R S Geha
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

3.  CD40 ligand expression deficiency in a female carrier of the X-linked hyper-IgM syndrome as a result of X chromosome lyonization.

Authors:  G de Saint Basile; M D Tabone; A Durandy; F Phan; A Fischer; F Le Deist
Journal:  Eur J Immunol       Date:  1999-01       Impact factor: 5.532

Review 4.  Update on the hyper immunoglobulin M syndromes.

Authors:  E Graham Davies; Adrian J Thrasher
Journal:  Br J Haematol       Date:  2010-02-23       Impact factor: 6.998

Review 5.  Microsatellite instability and DNA mismatch repair deficiency testing in hereditary and sporadic gastrointestinal cancers.

Authors:  Adrian Gologan; Antonia R Sepulveda
Journal:  Clin Lab Med       Date:  2005-03       Impact factor: 1.935

6.  Gene-targeted mice lacking the Ung uracil-DNA glycosylase develop B-cell lymphomas.

Authors:  Hilde Nilsen; Gordon Stamp; Sonja Andersen; Geza Hrivnak; Hans E Krokan; Tomas Lindahl; Deborah E Barnes
Journal:  Oncogene       Date:  2003-08-21       Impact factor: 9.867

7.  CD40 ligand expression is defective in a subset of patients with common variable immunodeficiency.

Authors:  M Farrington; L S Grosmaire; S Nonoyama; S H Fischer; D Hollenbaugh; J A Ledbetter; R J Noelle; A Aruffo; H D Ochs
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-01       Impact factor: 11.205

8.  Transcription-targeted DNA deamination by the AID antibody diversification enzyme.

Authors:  Jayanta Chaudhuri; Ming Tian; Chan Khuong; Katrin Chua; Eric Pinaud; Frederick W Alt
Journal:  Nature       Date:  2003-04-09       Impact factor: 49.962

9.  Human uracil-DNA glycosylase deficiency associated with profoundly impaired immunoglobulin class-switch recombination.

Authors:  Kohsuke Imai; Geir Slupphaug; Wen-I Lee; Patrick Revy; Shigeaki Nonoyama; Nadia Catalan; Leman Yel; Monique Forveille; Bodil Kavli; Hans E Krokan; Hans D Ochs; Alain Fischer; Anne Durandy
Journal:  Nat Immunol       Date:  2003-09-07       Impact factor: 25.606

10.  Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2).

Authors:  P Revy; T Muto; Y Levy; F Geissmann; A Plebani; O Sanal; N Catalan; M Forveille; R Dufourcq-Labelouse; A Gennery; I Tezcan; F Ersoy; H Kayserili; A G Ugazio; N Brousse; M Muramatsu; L D Notarangelo; K Kinoshita; T Honjo; A Fischer; A Durandy
Journal:  Cell       Date:  2000-09-01       Impact factor: 41.582

View more
  32 in total

Review 1.  Recent advances in the study of immunodeficiency and DNA damage response.

Authors:  Tomohiro Morio
Journal:  Int J Hematol       Date:  2017-05-26       Impact factor: 2.490

Review 2.  Prospects for modulating the CD40/CD40L pathway in the therapy of the hyper-IgM syndrome.

Authors:  Xiangxue Meng; Bin Yang; Wen-Chen Suen
Journal:  Innate Immun       Date:  2017-11-13       Impact factor: 2.680

3.  X-linked Hyper IgM Syndrome Presenting as Pulmonary Alveolar Proteinosis.

Authors:  Joel Gallagher; Juan Adams; Mary Hintermeyer; Troy R Torgerson; Jesus Lopez-Guisa; Hans D Ochs; Sara Szabo; Mina Salib; James Verbsky; John Routes
Journal:  J Clin Immunol       Date:  2016-06-20       Impact factor: 8.317

4.  A novel CD40LG deletion causes the hyper-IgM syndrome with normal CD40L expression in a 6-month-old child.

Authors:  Gabriela López-Herrera; José Luis Maravillas-Montero; Alexander Vargas-Hernández; Laura Berrón-Ruíz; Emmanuel Ramírez-Sánchez; Marco Antonio Yamazaki-Nakashimada; Francisco Javier Espinosa-Rosales; Leopoldo Santos-Argumedo
Journal:  Immunol Res       Date:  2015-05       Impact factor: 2.829

5.  Respiratory Complications in Patients with Hyper IgM Syndrome.

Authors:  Bobak Moazzami; Reza Yazdani; Gholamreza Azizi; Fatemeh Kiaei; Mitra Tafakori; Mohammadreza Modaresi; Rohola Shirzadi; Seyed Alireza Mahdaviani; Mahsa Sohani; Hassan Abolhassani; Asghar Aghamohammadi
Journal:  J Clin Immunol       Date:  2019-06-11       Impact factor: 8.317

6.  Activating PI3Kδ mutations in a cohort of 669 patients with primary immunodeficiency.

Authors:  M Elgizouli; D M Lowe; C Speckmann; D Schubert; J Hülsdünker; Z Eskandarian; A Dudek; A Schmitt-Graeff; J Wanders; S F Jørgensen; B Fevang; U Salzer; A Nieters; S Burns; B Grimbacher
Journal:  Clin Exp Immunol       Date:  2015-11-09       Impact factor: 4.330

7.  Visceral Leishmaniasis May Unmask X-linked Hyper-IgM Syndrome.

Authors:  Luis Ignacio Gonzalez-Granado; Nerea Dominguez-Pinilla; Fernando Gallego-Bustos; Jesús Ruiz-Contreras; Luis M Allende
Journal:  J Clin Immunol       Date:  2016-03-17       Impact factor: 8.317

Review 8.  An update on the use of immunoglobulin for the treatment of immunodeficiency disorders.

Authors:  Stephanie Albin; Charlotte Cunningham-Rundles
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

9.  B cells from African American lupus patients exhibit an activated phenotype.

Authors:  Laurence C Menard; Sium Habte; Waldemar Gonsiorek; Deborah Lee; Dana Banas; Deborah A Holloway; Nataly Manjarrez-Orduno; Mark Cunningham; Dawn Stetsko; Francesca Casano; Selena Kansal; Patricia M Davis; Julie Carman; Clarence K Zhang; Ferva Abidi; Richard Furie; Steven G Nadler; Suzanne J Suchard
Journal:  JCI Insight       Date:  2016-06-16

10.  PU.1 Expression in T Follicular Helper Cells Limits CD40L-Dependent Germinal Center B Cell Development.

Authors:  Olufolakemi Awe; Matthew M Hufford; Hao Wu; Duy Pham; Hua-Chen Chang; Rukhsana Jabeen; Alexander L Dent; Mark H Kaplan
Journal:  J Immunol       Date:  2015-09-11       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.